SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.8820
+0.0220 (2.56%)
At close: Jun 10, 2025, 4:00 PM
0.9000
+0.0180 (2.04%)
After-hours: Jun 10, 2025, 6:28 PM EDT
SCYNEXIS Revenue
SCYNEXIS had revenue of $257.00K in the quarter ending March 31, 2025, a decrease of -81.28%. This brings the company's revenue in the last twelve months to $2.63M, down -98.13% year-over-year. In the year 2024, SCYNEXIS had annual revenue of $3.75M, down -97.33%.
Revenue (ttm)
$2.63M
Revenue Growth
-98.13%
P/S Ratio
16.37
Revenue / Employee
$93,929
Employees
28
Market Cap
34.42M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SCYX News
- 13 days ago - SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - GlobeNewsWire
- 3 months ago - SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 8 months ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - GlobeNewsWire
- 10 months ago - SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 10 months ago - SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 months ago - SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports - GlobeNewsWire